ArticleLife (Basel, Switzerland)2026
Comparison of Long-Term Outcomes of Living-Donor Liver Transplantation in Hepatocellular Carcinoma Based on the Milan Criteria After Downstaging According to Degradable Starch Microspheres with Transcatheter Arterial Chemoembolization.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesHepatocellular carcinoma (HCC) is a disease with an increasing incidence. Liver transplantation (LT) represents the sole curative treatment option. Downstaging (DS) therapy represents an option in selecting suitable candidates for transplantation who initially have tumors exceeding the MC. Consequently, patients undergoing DS for MC have demonstrated comparable survival rates to those who initially met the MC. Degradable starch microspheres with transcatheter arterial chemoembolization (DSM-TACE), a type of TACE, have also been recently introduced in clinical practice.
methodsThis retrospective study encompassed 200 consecutive adult patients who underwent living-donor LT for HCC and cirrhosis at two different centers from March 2012 to December 2023. We aimed to compare long-term overall survival (OS) and recurrence-free survival (RFS) among patients with HCC who met the DSM-TACE criteria for MC following diagnosis, those initially within MC, and those outside MC following diagnosis.
resultsThe OS rate in the MC group was statistically comparable to that in the DS and beyond the MC groups. The MC and DS groups exhibited comparable long-term RFS rates. However, the MC and DS groups showed significantly better RFS rates than the beyond the MC group. Microvascular invasion (MVI), tumor size and number, and the beyond the MC group were identified as significant recurrence risk factors, whereas MVI alone was an independent prognostic factor.
conclusionsOur results showed good long-term OS and RFS in HCC patients following LDLT after staging into MC with DSM-TACE. Additionally, we achieved a more acceptable survival rate compared to other treatments in the group that underwent MC staging after DS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.